

# Octreotide (acetate)

Catalog No: tcsc0944



## Available Sizes

**Size:** 10mg

**Size:** 50mg



## Specifications

**CAS No:**

79517-01-4

**Formula:**

$C_{51}H_{70}N_{10}O_{12}S_2$

**Pathway:**

GPCR/G Protein

**Target:**

Somatostatin Receptor

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 29$  mg/mL (26.87 mM)

**Alternative Names:**

SMS 201-995 (acetate)


**Observed Molecular Weight:**

1079.29

## Product Description

Octreotide acetate, a long-acting synthetic analog of native somatostatin, inhibits **growth hormone**, **glucagon**, and **insulin** more potently.

**In Vivo:** Octreotide-treated groups show a significant reduction in the tumor volume when compared with saline group. Octreotide-PPSG (1.4 mg/kg, i.p.) shows greater antitumor effect than Octreotide-soln (100 µg/kg, i.p.). Octreotide-treatments results in significant inhibitory effect on the expression levels of SSTR2 and SSTR5 in primary HCC-bearing rats compared with the saline group. Octreotide-PPSG appears to inhibit the expression of SSTR2 and SSTR5 to a greater extent than that of Octreotide-soln treated group<sup>[1]</sup>. A test dose of octreotide acetate significantly decreases the serum gastrin level to approximately one third of the baseline in 2 hr and the effect lasted approximately for 6 hr. On day 21, treatment with sustained-release formulation of octreotide acetate (5 mg intramuscular, q 4 wk) is initiated<sup>[2]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!